Desmoyokin was first isolated from bovine muzzle epidermis and thought to be an epidermal desmosome-related protein. We previously demonstrated that the Desmoyokin gene is identical to the Ahnak gene, which is expressed ubiquitously and downregulated in neuroblastomas. It was assumed Ahnak/Desmoyokin was associated with epidermal cell adhesion, tumorigenesis, cell proliferation and differentiation, and embryonic development.
Ahnak/Desmoyokin is a phosphoprotein of exceptionally large size (700 kDa) and is encoded by an intronless gene located on human chromosome 11q12-13 (Shtivelman et al, 1992; Shtivelman and Bishop, 1993) . The Ahnak/Desmoyokin protein consists of three structural domains: a short NH 2 terminus of 251 amino acids, a large central domain of 4392 amino acids composed of highly conserved repeated elements, and a unique COOH terminus of 1000 amino acids. The latter contains putative regulatory elements including nuclear export and localization signals, as well as phosphorylation sites for protein kinase B and C (PKB and PKC) Nie et al, 2000; Sussman et al, 2001) . Although its precise biological function remains unknown, various experimental studies have suggested several possible roles for Ahnak/Desmoyokin (Haase et al, 1999; Sekiya et al, 1999; Gentil et al, 2001; Downs et al, 2002; Benaud et al, 2004) .
Expression and phosphorylation of Ahnak/Desmoyokin are regulated in a cell-cycle-dependent manner. The highest expression is observed in quiescent or differentiating cells and total phosphorylation is enhanced in proliferating cells (Shtivelman and Bishop, 1993) . Downregulation of Ahnak/ Desmoyokin in neuroblastoma cells, small cell lung carci-nomas, and Burkitt lymphomas (Shtivelman et al, 1992) , as well as in HRAS-transformed tumorigenic rat embryo fibroblasts (Zuber et al, 2000) , suggests the involvement of Ahnak/Desmoyokin in tumor formation. Ahnak/Desmoyokin binds and activates phospholipase C-g 1 in the presence of arachidonic acid (Sekiya et al, 1999) . In cardiomyocytes, Ahnak/Desmoyokin is associated with the regulatory b2 subunit of L-type calcium channels (Haase et al, 1999; Hohaus et al, 2002) , suggesting its potential implication in the regulation of channel activity. Ahnak/Desmoyokin also binds the EF-hand calcium-binding protein S100B in a strictly calcium-dependent manner, thus indicating that interaction with S100B may play a role in the regulation of cellular calcium homeostasis (Gentil et al, 2001) . Ahnak/Desmoyokin is expressed in the extra-embryonic membranes during gastrulation, but accumulates in the heart, neural crest, and its derivatives during organogenesis. This expression pattern during development is shared by several developmentally important gene products, including AP2.2, Hox-7, dHAND, eHAND, and twist (Kingsley et al, 2001) . Results of further analysis of Ahnak/Desmoyokin expression in mouse conceptuses have suggested that Ahnak/Desmoyokin may also be involved in tissue organization during mouse development (Downs et al, 2002) .
In human epidermis, Ahnak/Desmoyokin is localized mainly along the cell boundary, which implies some functional involvement in cell adhesion (Hieda and Tsukita, 1989) . On the other hand, Ahnak/Desmoyokin is localized in the nucleus in non-epithelial cells (Shtivelman and Bishop, 1993) . Recently, it has been found that Ahnak/Desmoyokin shuttles between nucleus and cytoplasm/plasma membrane, and that its translocation depends on extracellular calcium concentration Nie et al, 2000) , as well as on phosphorylation by PKB, which is activated by cell-cell contact inducing differentiation in cultured epidermal cells (Sussman et al, 2001) . More recent study of expression analysis in adult mouse tissue found that Ahnak/Desmoyokin is preferentially expressed in all muscular and epithelial cells of lining epithelium, but is absent from epithelium with secretory or absorptive functions (Gentil et al, 2003) .
These experimental investigations of the functional roles of Ahnak/Desmoyokin were mainly based on analyses using antibodies and expression vectors. Although these studies do suggest possible functions of Ahnak/Desmoyokin, its precise biological function could be more directly investigated with the ''loss of function'' analysis used in our study of Ahnak/Desmoyokin-deficient ES cells and mice.
Results
Generation of Ahnak/Desmoyokin-deficient ES cells and their proliferation and differentiation in vitro For an investigation of the functions of Ahnak/Desmoyokin by means of ''loss of function'' analysis, Ahnak/Desmoyokin-deficient ES cells were generated. To design the targeting construct, we cloned 129 mouse genomic DNA of Ahnak/Desmoyokin and constructed a replacement targeting vector that was expected to delete approximately 3.2 kb of genomic DNA encoding the ATG start codon, the N-terminal domain, and the head portion of the repeat domain of Ahnak/Desmoyokin ( Fig 1A) . The Ahnak/Desmoyokin targeting construct was electroporated into ES cells and selected for resistance to G418. We obtained seven independent ES clones that were found to accurately target the Ahnak/Desmoyokin genomic locus. Ahnak/Desmoyokin-deficient ES cells were then generated by a second targeting to neo-deleted heterozygous ES cells, which was confirmed by Southern blot analysis ( Fig 1B) . To analyze the proliferation of mutant ES cells, we evaluated the doubling time as described in Materials and Methods. There was no difference between wild-type and mutant ES cells, and both doubling times calculated were $ 10 h. To examine the differentiation of Ahnak/Desmoyokin-deficient ES cells, we used retinoic acid (RA) treatment to generate embryoid bodies. The morphology of these embryoid bodies showed no difference between wild-type and mutant ES cells, and both genotypes showed rhythmical contraction reflecting differentiation into cardiac muscle cells (Fig 2A, upper panel) . We also induced neural differentiation of mutant ES cells by cultivating them on PA6 feeder cells (Kawasaki et al, 2000) . Co-culture of mutant ES cells on PA6 feeder cells produced morphologically distinct neural differentiation similar to that of wild-type ES cells ( Fig  2A, lower panel ) . Furthermore, the embryoid bodies generated from both wild-type and mutant ES cells expressed the differentiation marker proteins of cardiac myocytes (sarcomeric a-actinin) (Takahashi et al, 2003) and neuroepithelial precursor cells (nestin) (Jin et al, 2002) ( Fig 2B) . These results indicate that Ahnak/Desmoyokin-deficient ES cells still have the developmental potential to differentiate into several lineages including cardiac cells and neural cells. In summary, proliferation and differentiation of Ahnak/ Desmoyokin-deficient cells were not affected in vitro.
Generation of Ahnak/Desmoyokin-deficient mice Ahnak/ Desmoyokin-deficient mice were generated for in vivo functional analysis. Two targeted heterozygous ES clones were micro-injected into host BDF1xBDF1 blastocysts. Southern blot analysis of genomic DNA extracted from the tails of the mice demonstrated that crosses of heterozygous mutant mice yielded offspring of all three possible genotypes at the Mendelian ratio ( Fig 1C, data not shown). An immunoprecipitation assay was used to detect Ahnak/Desmoyokin expression. An immunoprecipitation assay using the polyclonal antibody for the middle portion of AHNAK/desmoyokin (M-DY pAb) showed that the Ahnak/Desmoyokin protein was specifically immunoprecipitated from epidermal cell lysates of wild-type mice, but not from those of mutant mice ( Fig 1D) . To exclude the possibility of unwanted expression due to read-through of the downstream region, we developed a new polyclonal antibody against the C-terminal portion of Ahnak/Desmoyokin (C-DY pAb), for use in an immunoprecipitation assay, which demonstrated that no protein could be immunoprecipitated from epidermal cell lysates of mutant mice with C-DY pAb ( Fig 1D) . Western blot analysis of whole tissue extracts from skin, and immunohistochemical analysis of skin sections with C-DY pAb also verified that no protein was expressed in mutant mice ( Fig 1E, Fig 4, top panel) . These findings proved that the generation of Ahnak/Desmoyokin null mutant mice was successful.
Although Ahnak/Desmoyokin is supposed to play a role in mouse development, Ahnak/Desmoyokin-deficient mice showed no developmental defects or macroscopic abnormalities. These findings, together with those obtained with the in vitro experiments, lead us to conclude that Ahnak/ Desmoyokin deficiency has no effect on mouse development.
Analysis of epidermis from Ahnak/Desmoyokin-deficient mice To evaluate the effect of Ahnak/Desmoyokin deficiency on cell proliferation and differentiation in vivo, the skin of mutant mice was histologically analyzed. Skin sections from mutant mice at different ages during appendage development showed no abnormalities of hair follicles and sebaceous glands, suggesting that the skin appendage development of mutant mice was not affected ( Fig 3A) . As translocation of Ahnak/Desmoyokin to the plasma membrane is induced by PKC activation with 12-o-tetradecanoylphorbol-13-acetate (TPA) , we examined the effect of TPA stimulation on Ahnak/Desmoyokin-deficient epidermal cells. Both wild-type and mutant mice treated with TPA and BrdU showed similar increase in epidermal thickness and number of BrdU-labeled cells ( Fig 3B, bottom panel, Table I ), indicating that proliferation of Ahnak/Desmoyokin-deficient epidermal cells were not affected in vivo. In the immunohistochemical analysis of the skin sections, mutant epidermal cells expressed the epidermal differentiation markers keratin 1, keratin 5,
Figure 1
Targeted disruption of the Ahnak/Desmoyokin gene. (A) Structure of the Ahnak/Desmoyokin genomic locus and the targeting construct. The targeting vector was used to delete approximately 3.2 kb of genomic DNA, including the ATG start codon of Ahnak/Desmoyokin. N, the region encoding the N-terminal domain of 251 amino acids; repeated domain, the region encoding a repeating unit of 4392 amino acids; C, the region encoding C-terminal 1000 amino acids; 5 0 , 5 0 untranslated region; 3 0 , 3 0 untranslated region; neo, neomycin resistance gene; DT, diphtheria toxin gene; H, HindIII; E, EcoRI. Triangles flanking neo indicate loxP sites. The zigzag line connected to the 5 0 homologous region of the targeting vector represents the pBluescript vector backbone. Black boxes represent the 0.5-kb EcoRI fragment as a 5 0 probe and the 1.2-kb KpnI-EcoRV fragment as a 3 0 probe for Southern blot analysis. Arrows indicate primers for PCR genotyping (for primers A, B, and C, see Materials and Methods). (B, C) Southern blot analysis. Genomic DNA from ES cells (B) and tail (C) were prepared. The genomic DNA digested with HindIII or EcoRI were electrophoresed, transferred to a nylon membrane, and hybridized with a 5 0 or a 3 0 probe. Homologous recombination at the 5 0 portion was confirmed by detection of the wild-type allele as a 9.6-kb HindIII fragment, the targeted allele as 7.6-kb HindIII fragment, and the neo-deleted locus as a 13.4-kb HindIII fragment. Homologous recombination at the 3 0 portion was confirmed by detection of the wild-type allele as a 25.4-kb EcoRI fragment, and of the targeted and neo-deleted allele as a 19.3-kb EcoRI fragment (data not shown). Symbols: þ / þ , wild-type; À/À, homozygote; þ /À, heterozygote; del/ þ , neo-deleted heterozygous ES cells; del/À, second targeted ES cells. (D) Immunoprecipitation of Ahnak/Desmoyokin protein. Keratinocytes of wild-type and mutant mice were labeled with [ 35 S]methionine and protein extracts were analyzed by immunoprecipitation with the polyclonal antibodies against the middle portion of Ahnak/Desmoyokin (M), the C terminal portion of Ahnak/Desmoyokin (C), and STAT3 as a control (STAT3). Asterisk denotes non-specific bands that is also seen in immunoprecipitation with control normal rabbit serum. The signal of these bands did not change with increased protein volume loading, whereas the signal of 700 kDa (Ahnak/Desmoyokin) band was enhanced with increasing protein volume. (E) Western blot analysis of whole tissue extract from skin of mutant mice with C-DY pAb. involucrine, and laminin 5 in the appropriate locations ( Fig  4) , demonstrating that Ahnak/Desmoyokin-deficient epidermal cells showed normal differentiation.
Ahnak/Desmoyokin was first isolated from bovine muzzle epidermis as a desmosome-related protein (Hieda and Tsukita, 1989) , and thought to be involved in epidermal cell adhesion. To test this assumption, we examined the epidermal intercellular junctions of Ahnak/Desmoyokindeficient mice. For detailed analysis of the ultrastructure of intercellular junctions, we utilized immunoelectron microscopy. Ahnak/Desmoyokin localized at the periphery of desmosomal plaque in wild-type mice, but there was no protein expression of Ahnak/Desmoyokin in mutant mice. However, the ultrastructure of the intercellular junctions of mutant mice was indistinguishable from that of wild-type animals. Furthermore, localization of Desmocollin, the major constituent of desmosome, was not affected ( Fig 5) . These findings clearly indicated that Ahnak/Desmoyokin is not functionally associated with epidermal desmosomes nor implicated in epidermal cell adhesion.
Tumorigenesis of Ahnak/Desmoyokin-deficient mice Although no spontaneous tumor formation was observed in mutant mice up to 2 y of age (data not shown), the findings of previous studies demonstrating downregulation in malignant tumor cell lines (Shtivelman et al, 1992) and tumorigenic HRAS-transformed rodent cells (Zuber et al, 2000) prompted us to examine whether Ahnak/Desmoyokin deficiency affects susceptibility to carcinogen application. To this end, we performed two-stage carcinogenesis experiments with an initiator, 7,12-dimethylbenz(a)anthracene (DMBA), plus a tumor promotor, TPA on the skin of wild-type and mutant mice. DMBA introduces a point mutation in codon 61 (A 182 to T) of the c-Ha-ras gene, and application of TPA after initiation with DMBA leads to the appearance of papillomas, some of which can progress to malignant carcinomas (Quintanilla et al, 1986; Finch et al, 1996) . Since our results showed no significant difference in tumor formation rates between wild-type and mutant mice ( Fig 6) , and no malignant tumors were observed in this experiment, we concluded that Ahnak/Desmoyokin deficiency has no or minimal effect on tumorigenesis, and that Ahnak/Desmoyokin may not be implicated in malignant cell transformation in vivo.
Discussion
In this study, we evaluated the possible roles for Ahnak/ Desmoyokin suggested in previous studies, by means of ''loss of function'' analysis, which enabled us to investigate more directly its precise biological function. Viability and fertility of mutant mice clearly indicated that Ahnak/Desmoyokin is not a critical gene for mouse development, unlike what could be expected from its expression pattern in developmental stages. Ahnak/Desmoyokin was first isolated from bovine muzzle epidermis as an epidermal desmosome-related protein, and therefore was named Desmoyokin (Hieda and Tsukita, 1989) . Later studies found that Ahnak/Desmoyokin local-ized substantially in the non-desmosomal areas of the cell membrane of human keratinocytes with slight accumulation around desmosomes (Masunaga et al, 1995) , thus suggesting its functional role in cell adhesion not directly associated with, but stabilizing epidermal desmosomes. However, analysis of its localization could not fully address the question as to whether Ahnak/Desmoyokin is in fact related to epidermal cell adhesion. Phenotypic analysis of skin sections from mutant mice provided conclusive evidence that Ahnak/Desmoyokin is neither involved in stabilization of epidermal desmosomes nor related to epidermal cell adhesion.
Recently, Ahnak/Desmoyokin was found to be localized within small cytoplasmic vesicles called enlargosomes, which are thought to be a new type of vesicle capable of rapid, calcium-dependent exocytosis (Borgonovo et al, 2002) . Fusion of these vesicles induces redistribution of Ahnak/Desmoyokin to the external cell surface and enlargement of the plasma membrane. Enlargosomes have Wild-type ( þ / þ ), heterozygous ( þ /À), and mutant (À/À) mice were treated with TPA or acetone vehicle. The average numbers of BrdUlabeled cells/100 basal cells with observation of 3000 basal cells were shown. Number in parentheses indicates number of mice analyzed.
Figure 4
Immunohistochemical analysis of skin sections. Immunostaining of skin sections from wild-type ( þ / þ ) and mutant (À/À) mice with primary antibodies against C-terminal portion of Ahnak/Desmoyokin (C-DY), K1, K5, Involucrine, and Laminin 5. White dashed line indicates basement membrane zone. Scale bar, 100 mm. been proposed to participate in cell membrane differentiation and repair (Borgonovo et al, 2002) . This finding, together with that of its regulated expression and phosphorylation in a cell-cycle-dependent manner (Shtivelman and Bishop, 1993) , led us to speculate that Ahnak/ Desmoyokin deficiency might affect cell proliferation and differentiation. However, our ''loss of function'' analysis conducted with mutant ES cells and epidermal cells left us no choice but to conclude that Ahnak/Desmoyokin by itself is unlikely to play a crucial role in cellular proliferation and differentiation.
Susceptibility of mice in two-stage carcinogenesis protocol is influenced by genetic background. For example, C57BL/6 mice are resistant, whereas 129 mice are sensitive to TPA promotion in the protocol (Reiners Jr and Singh, 1997; Guo et al, 1999) . In our experiments, we obtained the mutant mice by mating of the chimeric mice generated from R1-ES cells (129 strain) with C57BL/6 mice. Therefore, the genetic background of the mutant mice is the mixture of 129 and C57BL/6. Although, our tumor studies could be affected by genetic resistance, the comparison among littermates allowed us to conclude that Ahnak/Desmoyokin deficiency has only a minimal effect on tumorigenesis and malignant cell transformation in vivo.
Recently, Baudier's group reported their results of a ''loss of function'' analysis of Ahnak/Desmoyokin using downregulation with a small interfering RNA, and proposed that Ahnak/Desmoyokin might fulfill a function in regulating cortical actin cytoskeleton organization and cell membrane cytoarchitecture. They found that downregulation of Ahnak/ Desmoyokin in MDCK cells using specific siRNA prevented cortical actin cytoskeleton from reorganizing, which in turn resulted in reduced cell height (Benaud et al, 2004) . However, in our study Ahnak/Desmoyokin-deficient epidermal cells appeared morphologically normal in vivo. There may be two possible explanations for these discrepant observations. One is that siRNA designed against central repeated elements of Ahnak/Desmoyokin may have impaired unknown proteins containing similar sequences, such as titin, which has a PEVK region similar to the central repeated sequence of Ahnak/Desmoyokin (Wernyj et al, 2001) . The other explanation is that acute loss of Ahnak/Desmoyokin caused by siRNA might be phenotypically different from its constitutive elimination resulting from the knockout procedure. For example, acute loss of Rb caused by the Cre-loxP system and germline loss of the Rb function showed different phenotypes in cell-cycle regulation, and this difference can be supposed to have been caused by functional compensation due to the prolonged absence of Rb in germ line mutation (Sage et al, 2003) . This notion raises the possibility of the existence of compensating proteins functionally related to Ahnak/Desmoyokin. The mutant mice and ES cells generated for our study can be expected to become useful tools for the further investigation of existence of compensating and redundantly contributing proteins. Although Ahnak/Desmoyokin may yet have important functions as previously reported, we were able to demonstrate that its functional mechanism is not so simple as to show overt phenotypes following the knockout procedure. In that respect, our study is thought to have made a major contribution towards the full clarification of the true functions of Ahnak/Desmoyokin in living organisms.
Materials and Methods
Isolation of the Ahnak/Desmoyokin gene and construction of the targeting vector The Ahnak/Desmoyokin genomic DNA was 
Figure 6
Two-stage chemical skin carcinogenesis experiments. Percentages of tumor-free mice during the 20-wk duration of the experiment. Only one or two tumors were observed in tumor-bearing mice of each genotype. There were no major differences in tumor formation rates among wild-type ( þ / þ , black bars), heterozygous ( þ /À, gray bars), and mutant (À/À, white bars) mice. The actual numbers of tumor-free mice of each genotype and time point were denoted on the bars. obtained from a 129/SvJ mouse lambda genomic library (Stratagene, La Jolla, California). A 1.3-kb blunted EcoRI-NotI fragment of the negative selection marker DT-A, containing the diphteria toxin A-fragment from pMC1DTpA, was inserted into blunted BamHI-NotI sites of pBluescript II KS ( þ ) vector (pBS) (Stratagene), resulting in pBS-DT. A 6.5-kb blunted HindIII-blunted SalI fragment (SalI from the Lambda FIX II vector) of genomic DNA was inserted into the SmaI site of pBS-DT, resulting in pankL-DT. A 1.7-kb EcoRI-blunted NotI fragment containing PGK-Neo flanked by two loxP sites was inserted into the EcoRI-blunted HindIII sites of pBS, resulting in pBS-Neo. A 1.7-kb EcoRI-SalI fragment from pBS-Neo was inserted into the EcoRI-SalI sites of pankL-DT, and a 2.7-kb of blunted EcoRI-SmaI fragment of genomic DNA containing 5 0 noncoding region of Ahnak/Desmoyokin into the blunted KpnI-SmaI sites of pBS, resulting in pBS-S. Finally, a 9.5-kb blunted SalI-NotI fragment of pankL-DT was inserted into the SmaI-NotI sites of pBS-S, resulting in a 15.1-kb targeting vector. Prior to its electroporation into embryonic stem cells, the targeting vector was linearized with NotI site at the 3 0 end of the DT-A cassette.
Generation of mutant ES cells and mice 3 Â 10 7 R1-ES cells were electroporated with 75 mg of the linearized targeting construct (0.4 cm cuvette, 240 V, 500 mF) and then plated onto feeder cells. After 7 d selection with 150 mg per mL of G418, resistant colonies were harvested. Each colony harvested was divided for culture and PCR screening. Positive clones were expanded and confirmed by Southern blot analysis.
For the second targeting, targeted ES cells were transiently transfected with expression plasmid encoding Cre recombinase. After Cre-mediated recombination, neo-deleted ES clones were electroporated with the same targeting vector as used for the first targeting. Subsequently, G418 selection and PCR screening were processed in the same manner as for the first targeting.
To generate Ahnak/Desmoyokin-deficient mice, monoallelically targeted ES clones with a normal karyotype were injected into BDF1xBDF1 blastocysts. PCR genotyping was performed with one forward primer, which is specific for the genomic sequence present in both the wild-type and targeted allele (primer A, 5 0 -GGGCA-GGTTTCCCCCTTTCTGTCTTTATTG-3 0 ), and two reverse primers. One of these is specific for the neo-cassette poly-A addition signal sequence present in the targeted allele (primer B, 5 0 -CGCATCGCC-TTCTATCGCCTTCTTGACGAG-3 0 ), and the other for the sequence present in the wild-type allele disrupted by gene targeting (primer C, 5 0 -GGCCTTCCACAGTCATTTGGTCATTTCTGC-3 0 ). Primer pairs A and B yielded a 400-bp fragment from the mutant alleles, which was then digested with the SpeI producing 300-and 100-bp fragments. Primer pairs A and C yielded a 400-bp fragment from the wild-type allele, which was the same size as the mutant but not digested by SpeI. PCR screening as described above could discriminate among wild-type, heterozygous, and homozygous mice.
Southern blot analysis The 0.5-kb EcoRI fragment and the 1.2kb KpnI-EcoRV fragment, located, respectively, upstream and downstream of the homologous region of the targeting vector, were used as probes. Genomic DNA of mutant ES cells and mutant mice was purified and digested with either HindIII or EcoRI, fractionated on a 0.7% agarose gel, transferred to a nylon membrane (Amersham, Buckinghamshire, UK), and hybridized with a 32 P-labeled probe.
Preparation of antibody Preparation of the polyclonal antibody for the middle portion of Ahnak/Desmoyokin (designated M-DY pAb in this study) was previously described (Hashimoto et al, 1993) .
To obtain the polyclonal antibody, which specifically recognizes the C-terminal portion of Ahnak/Desmoyokin (designated C-DY pAb), a 300-bp genomic DNA fragment, which encodes from threonine 5419 to glysine 5519 of Ahnak/Desmoyokin, was subcloned in-frame into expression vector pGEX-5X-3 (Amersham). The glutathione-S-transferase (GST)-fusion protein was produced and purified with a glutathione-sepharose 4B column (Amersham) for immunization of rabbits. The obtained anti-Ahnak/Desmoyokin serum was further purified with a glutathione-sepharose column, to which GST was bound, for exclusion of the anti-GST antibody.
Immunoprecipitation and western blotting 2 Â 10 6 epidermal cells obtained from newborn mice were labeled in methionine-free medium containing 250 mCi [ 35 S]methionine per mL for 1h. The labeled cells were solubilized in 500 mL of RIPA buffer (10 mM Tris, pH 7.5, 1% NP40, 0.1% sodium deoxycholate, 0.1% SDS, 150 mM NaCl, 1 mM EDTA) containing 10 mg per mL of protease inhibitor (complete EDTA free; Roche Diagnostics, Mannheim, Germany). The protein G-sepharose beads coupled with each anti-serum (M-DY pAb, C-DY pAb, and normal rabbit serum) were mixed with 80 mL of the supernatants of the labeled cell lysates and incubated overnight at 41C. The sepharose beads were washed with RIPA buffer and the immunoprecipitated proteins were analyzed by means of 5% SDS-polyacrylamide gel electrophoresis and autoradiography.
The lysates (20 mg of protein) from frozen tissue specimens of the skin were separated on a 5% SDS-polyacrylamide gel and transferred to polyvinylidene difluoride membrane (Millipore, Billerica, Massachusetts) for 2 h at 300 mA. The transfers were subsequently incubated with C-DY pAb (1:200 dilution) overnight at 41C. Immunoreactive protein bands were visualized by the ECL reaction kit (Amersham).
In vitro differentiation of mutant ES cells Embryoid body formation from ES cells was performed as described previously (Gajovic et al, 1998) . During the first 4 d, 400 ES cells were cultured in suspension for embryoid body preparation with or without 1 mM all trans-RA (Sigma, St Louis, Missouri), and transferred to gelatincoated cell culture dishes with medium lacking RA, and further cultured for 5 d.
For neural differentiation, stromal cell-derived inducing activityinduced neurogenesis of ES cells was performed as described previously (Kawasaki et al, 2000) . In this procedure, ES cells were plated on fixed PA6 cells at a density of 2 Â 10 4 cells per 35 mm culture dish and cultured for 10 d.
Immunofluorescence After fixation with 4% paraformaldehyde in 0.1 M phosphate-buffered saline (PBS), pH 7.4, for 15 min, cells were treated with 0.1% Triton X-100 (Nacalai, Kyoto, Japan) in 0.1 M PBS for 15 min. After BSA block (5% BSA in PBS), cells were incubated with primary antibodies at 41C overnight. Five micrometer cryosections of the skin obtained from newborn mice were fixed with cold acetone and blocked in 10% goat serum in PBS with 0.1% Tween-20 for 30 min. Fixed sections were incubated with primary antibodies at 41C overnight. The following primary antibodies were used: mouse anti-a-actinin (sarcomeric) (1:600 dilution) (Sigma), mouse anti-nestin (1:400 dilution) (BD Biosciences Pharmingen, San Diego, California), rabbit anti-K1, K5, involucrine (1:200 dilution) (BabCO, Richmond, California), laminin 5 (GB3, gift of professor Ortonne) (1:100 dilution), C-DY pAb (1:100 dilution). Fluorescence labeling was performed with Alexa Fruor 488-conjugated anti-mouse IgG antibody (Molecular Probes, Eugene, Oregon) (1:1000 dilution), or FITC-conjugated anti-rabbit IgG antibody (Cappel, Aurora, Ohio) (1:500 dilution). The fluorescence signals were detected with Olympus IX70 microscope (Olympus, Nagano, Japan).
Proliferation assay of mutant ES cells and epidermal cells
The log-phase ES cells were plated at a density of 2 Â 10 5 cells per well on 24-well plates, and counted every 4 h for three times independently. These counts were plotted as cells per mL ( Â 10 5 ) against time (h). The average doubling time to the log phase of the growth curves were calculated.
For BrdU-labeling assay, Ahnak/Desmoyokin þ / þ (n ¼ 6), Ahnak/ Desmoyokin þ /À (n ¼ 6), and Ahnak/Desmoyokin À/À (n ¼ 6) mice were shaved at 6 wk of age. Two days later, the mice were topically treated with 2.5 mg of TPA in 100 mL of acetone or the acetone vehicle twice a week for 2 wk (four doses total). Forty-eight hours after the last treatment, the mice received intraperitoneal injection of BrdU (100 mg per g body weight) in PBS. Thirty minutes later, the mice were euthanized and the paraffin-embedded skin sections were prepared. BrdU staining of the skin sections were performed with rat monoclonal anti-BrdU (Oxford Biotechnology, Oxford, UK) and biotinylated rabbit anti-rat IgG (DAKO, Carpinteria, California). Labeled nuclei were counted for each genotype and treatment.
Immunoelectron microscopy Post-embedding immunogold electron microscopy was performed as previously described (Ishida-Yamamoto et al, 1996) . Briefly, mouse skin tissue was cryoprotected with 15% glycerol-PBS, rapidly cryofixed with liquid propane at À1901C, subjected to cryosubstitution in methanol at À801C, and embedded in Lowicryl K11M according to the manufacturer's protocol (Chemische Werke Lowi, Waldkraiburg, Germany). Ultrathin sections were transferred to formvar-coated nickel grids and incubated with M-DY pAb (1:600 dilution), C-DY pAb (1:300 dilution), and mouse monoclonal anti-desmocollin 2, 3 antibody (Parrish et al, 1990) (1:100 dilution) for 1 h at 371C. This was followed by incubation with 10 or 5 nm gold-conjugated goat antirabbit IgG (Amersham) (1:10 dilution) for 1 h at 371C. The sections were stained with uranyl acetate and examined with a JEM-2000EX electron microscope (JEOL, Tokyo, Japan).
Two-stage chemical skin carcinogenesis experiments
For chemical carcinogenesis studies, Ahnak/Desmoyokin þ / þ (n ¼ 5), Ahnak/Desmoyokin þ /À (n ¼ 8), and Ahnak/Desmoyokin À/À (n ¼ 8) mice were shaved at 7-9 wk of age. Two days later, 100 mg of DMBA in 200 mL of acetone was applied to the dorsal skin of the mice. From 1 wk after DMBA application, a twice per week application of 2.5 mg of TPA in 100 mL of acetone was continued for the next 20 wk, and the mice were checked for skin tumors every week. At the end of 20 wk, the mice were euthanized and their skin sections processed for histology. All animal studies have been approved by the institutional review board.
